I had a question regarding the modularity and the complexity of modifying Bisantrene for FTO.
I noticed that scientists at the city of hope are working on improving the use of Bisantrene in the area of FTO by changing the structure or perhaps the use cases of the drug to enhance it.
So, I got a question for Dr T - how likely is it for a drug like bisantrene to be modified in the lab to be more effective in the area of FTO if it doesn’t achieve success and what process do they go through to achieve this? Thanks!
Pillar 1 - FTO (new thread), page-374
-
- There are more pages in this discussion • 2,618 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |